Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable advanced therapies and vaccine production, has completed €2 million expansion of its Nivelles, Belgium site. The investment aims to deliver greater support and supply chain security to biomanufacturers.
TFBS Bioscience, a GMP viral vector contract development and manufacturing organization (CDMO) in the Asia-Pacific (APAC) region providing the first viral vector manufacturing in Taiwan, has entered a partnership with Univercells Technologies, a provider of novel biomanufacturing technologies for flexible and scalable viral production. TFBS will leverage the scale-X carbo mid-scale fixed-bed bioreactor from Univercells for good manufacturing practice (GMP) viral vector operations at the expanding state-of-the-art New Taipei City facility.
TFBS will leverage the scale-X carbo mid-scale fixed-bed bioreactor from Univercells Technologies for good manufacturing practice (GMP) viral vector operations at the expanding state-of-the-art New Taipei City facility.
Amidst another wave of Covid-19, Senegal is preparing a manufacturing plant of its own as the country and its continent severely lag behind the rest of the world on vaccination rates.
Univercells Technologies has introduced a new platform in the NevoLine biomanufacturing product family—the NevoLine Upstream platform.